ParilloJE. Pathogenetic mechanisms of septic shock. N. Engl. J. Med1993; 328: 1471–1477.
2.
HolmesCL.PatesBMRussellJAWalleyKR. Physiology of vasopressin relevant to management of septic shock. Chest2001; 120: 989–1002.
3.
LandryDWLevinHR.GallantEM.AshtonRC.SeoSD'AllessandroDOzMCOliverJA. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation1997; 95: 1122–1125.
4.
LandryDWLevinHRGallantEMSeoS.D'AllessandroDOzMCOliverJA. Vasopressin deficiency contributes to the vasodilation of septic shock. Crit Care Med1997; 25: 1279–1282.
5.
MalayMBAshtonRCLandryDWTownsendRN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J. Trauma.1999; 47: 699–703.
6.
HolmesCLWalleyKRChittockDRLehmanTRussellJA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med.2001; 27: 1416–1421.
7.
PatelBMChittockDR.RussellJA.WalleyKR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology2002; 96: 576–582.
8.
LandryDWOliverJA. The pathogenesis of vasodilatory shock. N. Eng. J. Med.2001; 345: 588–595.
9.
O'BrienAJWilsonAJSibbaldRSingerMClappLH. Temporal variation in endotoxin-induced vascular hyporeactivity in a rat mesenteric artery organ culture model. British Journal of Pharmacology2001; 133, 351–360.
10.
O'BrienAJClappLHSingerM. Terlipressin for norepinephrine-resistant septic shockLancet.2002; 359, 1209–10.
11.
HamuYKanmuraYTsuneyoshiIThe effects of vasopressin on endotoxin-induced attenuation of contractile responses in human gastroepiploic arteries in vitro. Anesth Analg;1999; 81: 542–8.